You are here

ACC

 
 

Medicare beneficiaries who received an implantable pulmonary artery pressure (PAP) sensor had a statistically significant 45 percent lower rate of heart failure hospitalizations and reduced costs at six months, according to a retrospective cohort study.

 
 - CardioMEMS
ACC.17: Medicare beneficiaries implanted with CardioMEMS system have lower rate of heart failure hospitalizations

Medicare beneficiaries who received an implantable pulmonary artery pressure (PAP) sensor had a statistically significant 45 percent lower rate of heart failure hospitalizations and reduced costs at six months, according to a retrospective cohort study.

 - Surgery
ACC.17: LAAO at the time of cardiac surgery may reduce thromboembolism, mortality

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

 - Mary Norine Walsh
Mary Norine Walsh begins role as ACC president

On the final day of this year’s American College of Cardiology (ACC) conference, Mary Norine Walsh, MD, assumed her role as the president of the organization.

 - Robert Giugliano
ACC.17: EBBINGHAUS trial shows statins don’t affect cognitive ability

Findings presented at the American College of Cardiology’s 66th Annual Scientific Session show that adding a cholesterol-lowering drug to treatment with a statin has no effect on cognition and thinking.

 - Philip Wells
ACC.17: Rivaroxaban more effective in preventing VTE recurrence than aspirin, EINSTEIN CHOICE study shows

New research looking at the efficacy of rivaroxaban, an oral blood-thinning medication compared to aspirin yielded positive results for the complex drug, showing that it can limit the recurrence of a venous thromboembolism (VTE) without increasing the risk for bleeding.